Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181
Status:
Completed
Trial end date:
2018-08-02
Target enrollment:
Participant gender:
Summary
AGT-181 is a fusion protein containing alpha-L-Iduronidase that is intended to deliver the
enzyme peripherally and to the brain, when administered intravenously. This study is an
extension of a safety and dose ranging study to obtain long term safety and exposure data, as
well as information on the biological activity of the investigational drug